Evolus, Inc.

NasdaqGM:EOLS Rapporto sulle azioni

Cap. di mercato: US$797.9m

Evolus Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

David Moatazedi

Amministratore delegato

US$11.2m

Compenso totale

Percentuale dello stipendio del CEO6.1%
Mandato del CEO6.5yrs
Proprietà del CEOn/a
Durata media del management3yrs
Durata media del Consiglio di amministrazione6.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Nov 13
Evolus, Inc. (NASDAQ:EOLS) Might Not Be As Mispriced As It Looks After Plunging 26%

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Oct 22
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus Continues To Make Progress

Aug 02

Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Aug 02
Evolus, Inc. (NASDAQ:EOLS) Looks Just Right With A 32% Price Jump

Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Jul 13
Evolus (NASDAQ:EOLS) Is Making Moderate Use Of Debt

Evolus: Chiseling Away At The Aesthetic Market

May 22

Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

May 10
Analysts Are Updating Their Evolus, Inc. (NASDAQ:EOLS) Estimates After Its First-Quarter Results

Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Mar 20

The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 10
The Evolus, Inc. (NASDAQ:EOLS) Full-Year Results Are Out And Analysts Have Published New Forecasts

Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Jan 18
Evolus, Inc. (NASDAQ:EOLS) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Jan 18
Evolus, Inc.'s (NASDAQ:EOLS) Shares Climb 27% But Its Business Is Yet to Catch Up

Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Jun 16
Would Evolus (NASDAQ:EOLS) Be Better Off With Less Debt?

Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Nov 06
Does Evolus (NASDAQ:EOLS) Have A Healthy Balance Sheet?

Evolus concludes certain royalty payments related to settlement of IP rights dispute

Sep 21

Evolus: Turning That Frown Upside Down

Sep 11

Evolus appoints Experian's exec as CFO

Aug 30

Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Aug 04
Is Evolus (NASDAQ:EOLS) Using Too Much Debt?

Evolus Q2 2022 Earnings Preview

Aug 01

Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Mar 21
Is Evolus (NASDAQ:EOLS) Using Debt Sensibly?

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di David Moatazedi rispetto agli utili di Evolus?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$55m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$60m

Dec 31 2023US$11mUS$688k

-US$62m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$66m

Mar 31 2023n/an/a

-US$72m

Dec 31 2022US$4mUS$597k

-US$74m

Sep 30 2022n/an/a

-US$79m

Jun 30 2022n/an/a

-US$79m

Mar 31 2022n/an/a

-US$71m

Dec 31 2021US$4mUS$572k

-US$47m

Sep 30 2021n/an/a

-US$139m

Jun 30 2021n/an/a

-US$131m

Mar 31 2021n/an/a

-US$137m

Dec 31 2020US$3mUS$527k

-US$163m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$99m

Dec 31 2019US$2mUS$550k

-US$90m

Sep 30 2019n/an/a

-US$88m

Jun 30 2019n/an/a

-US$73m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$6mUS$362k

-US$47m

Compensazione vs Mercato: La retribuzione totale di David ($USD 11.24M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 3.18M ).

Compensazione vs guadagni: La retribuzione di David è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

David Moatazedi (46 yo)

6.5yrs

Mandato

US$11,240,447

Compensazione

Mr. David Moatazedi is Independent Director at Biomerica Inc. from December 07, 2022. He has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Mo...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
David Moatazedi
President6.5yrsUS$11.24mNessun dato
Sandra Beaver
Chief Financial Officer2.2yrsUS$2.46m0.052%
$ 413.1k
Rui Avelar
Chief Medical Officer and Head of Research & Development10.8yrsUS$2.93m0.31%
$ 2.5m
Nareg Sagherian
Head of Global Investor Relations & Corporate Communicationsless than a yearNessun datoNessun dato
Jeffrey Plumer
General Counselno dataNessun datoNessun dato
Kurt Knab
Vice President of Sales6.1yrsNessun datoNessun dato
Tomoko Yamagishi-Dressler
Chief Marketing Officer1.3yrsNessun dato0.016%
$ 128.6k
Jessica Novak
Senior Vice President of Human Resources3yrsNessun datoNessun dato

3.0yrs

Durata media

46yo

Età media

Gestione esperta: Il team dirigenziale di EOLS è considerato esperto (durata media dell'incarico 3 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
David Moatazedi
President6.5yrsUS$11.24mNessun dato
David Gill
Independent Director6.8yrsUS$256.03k0.043%
$ 346.5k
Simone Blank
Director6.8yrsUS$235.03k0.86%
$ 6.9m
Albert White
Independent Directorless than a yearNessun datoNessun dato
Vikram Malik
Chairman of the Board6.8yrsUS$271.03k0.37%
$ 3.0m
Karah Parschauer
Independent Director5.3yrsUS$249.03k0.049%
$ 393.7k
Brady Stewart
Independent Director2.8yrsUS$222.03k0.071%
$ 564.5k

6.5yrs

Durata media

54yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di EOLS sono considerati esperti (durata media dell'incarico 6.5 anni).